Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 36 Neoplasm Metastasis 8 Ovarian Neoplasms 5 Sarcoma 4 Neoplasms 4 Lymphoma, Non-Hodgkin 4 Pancreatic Neoplasms 3 Multiple Myeloma 3 Lymphoma 3 Glioma 3 Endometrial Neoplasms 3 Carcinoma, Renal Cell 3 Wilms Tumor 2 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma, Ewing 2 Rhabdomyosarcoma 2 Rhabdoid Tumor 2 Recurrence 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Osteosarcoma 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Neuroblastoma 2 Neoplasms by Site 2 Medulloblastoma 2 Lymphoma, Mantle-Cell 2 Lung Neoplasms 2 Liposarcoma 2 Histiocytosis, Langerhans-Cell 2 Hereditary Sensory and Autonomic Neuropathies 2

Interventions

Letrozole 2 ribociclib 1 palbociclib 1 abemaciclib 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

HR+/HER2- Breast Cancer × palbociclib × 90 days × Clear all

NCT07492641 2026-06-03

KANDELA-302

BeOne Medicines

Phase 3 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡